Biotech Values

[Bickema]

RVNC - hard to pinpoint the weakness in today's price action with the entire market sell off.

But a few things of note was RVNC won't be reporting any meaningful revenue wrt to the Teoxane fillers until the end of the year due to sampling.

Also the cash burn for 2020 looks pretty high at: 2020 GAAP operating expense to be in the range of $272 million to $280 million and non-GAAP operating expense, which excludes depreciation and stock-based compensation, in the range of $222 million to $230 million.

Then's there's always the chance that algo's are selling off the "RVNC misses by .05" headline which is common in non revenue producing bios.